Introduction
The Prostatitis Consensus Workshop sponsored by the National Institutes of Health (NIH) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in December 1995 was a major landmark event in the history of prostatitis research. This meeting resulted in the general acceptance of the NIH classification system for the prostatitis syndromes. This classification system recognized that our understanding of the cause of disease in most patients in whom chronic prostatitis was previously diagnosed is limited and raised the possibility that structures other than the prostate gland may be important in the pathogenesis of chronic prostatitis. The "new" NIH classification system [1] renames the traditional classification of acute and chronic bacterial prostatitis, respectively, as categories I and II. Category III (chronic prostatitis/chronic pelvic pain syndrome or CP/CPPS) recognizes that pain is the main symptom characterizing the "nonbacterial chronic prostatitis" syndromes and was defined as "the presence of genito-urinary pain in the absence of uropathogenic bacteria detected by standard microbiological methodology." This category is further categorized into inflammatory (category IIIA) and noninflammatory (category IIIB) CP/CPPS. A completely new category, asymptomatic inflammatory prostatitis (category IV), describes an important inflammatory condition that had been more or less ignored in the previous classification system. The pivotal 1995 NIH/NIDDK workshop also led indirectly to the formation in 1997 of the NIH Chronic Prostatitis Collaborative Research Network (CPCRN). The network is a multi-institutional, collaborative research endeavor whose mandate is to further define the disease and its cause and epidemiology, describe its natural history, develop validated outcome measures, and determine better methods of treatment and prevention [2] . This paper summarizes the progress and challenges in meeting the ambitious CPCRN agenda.
Development of a Validated Outcome Index
The first step in accomplishing the CPCRN agenda was to develop a reliable and valid index of symptoms and impact on quality of life (QoL) for the evaluation of patients with CP/CPPS. The CPCRN conducted a structured literature review of previous work to provide a foundation for the new instrument and then conducted a series of focus groups consisting of patients with prostatitis. From these efforts, the most important symptoms and effects of the condition were identified. Based on formal cognitive testing, expert panel review, and formal validation testing in a large group of patients with chronic prostatitis and two control populations of patients with benign prostatic hyperplasia and healthy men, the initial draft of 55 items eventually yielded an index of nine items that addressed the three most important parameters of a patient's experience with chronic prostatitis. The primary component was pain, which was captured in four items focused on location, severity, and frequency; urinary function was captured in two items (one irritative and one obstructive) and QoL was captured in three items related to the effect of symptoms on daily activities. The NIH Chronic Prostatitis Symptom Index (CPSI) provided a practical but comprehensive evaluative instrument that was easily self-administered, psychometrically robust, and highly discriminative [3••] .
The CPCRN assessed the responsiveness of the NIH-CPSI to changes over time and defined thresholds for changes perceptible to patients [4] . The NIH-CPSI total score, pain, and QoL scores were highly responsive in the improved group, although the urinary score showed minimal responsiveness. A six-point decline in the NIH-CPSI total score proved the optimal threshold to predict treatment response that was meaningful to the patient. The NIH-CPSI has also proven useful in clinical practice [5] . Physicians have successfully used the NIH-CPSI to identify the specific symptoms of patients with prostatitis, determine their relative severity, and most importantly, track response to clinical therapy over time. The NIH has sponsored a translation and linguistic validation of the NIH-CPSI into Spanish [6] and French Canadian [7] . The Spanish and French Canadian versions of the NIH-CPSI have proven acceptable for clinical use with Spanish and French Canadian speakers in North America (and have also been used outside North America for Spanish and French speakers) and have allowed inclusion of these populations in clinical studies.
In summary, the NIH-CPSI total score and pain and QoL scores (but not necessarily the urinary score) provide valid and reliable indicators of disease severity, are responsive to improvement over time, are appropriate endpoints for clinical trials, and can be used as a clinical instrument for following patients with CP/CPPS in clinical practice.
Epidemiology
Important epidemiologic goals of the CPCRN were to characterize men with CP/CPPS and to determine the natural treated history. The CPCRN developed a prospective longitudinal chronic prostatitis cohort (CPC) study in which patients with CP/CPPS were comprehensively studied and then followed over time. Baseline analysis of the first 488 men screened into the CPC study allowed an important description of the patient in whom CP/CPPS is diagnosed. The patients underwent extensive demographic and clinical baseline screening assessment, symptom and QoL data collection employing the NIH-CPSI, various clinical procedures including physical examination, the standard four-glass test, uroflowmetry, and semen sample analyses. The CPC study represented the largest comprehensive study of a cohort of men with CP/CPPS recruited specifically for the evaluation and study of this condition. The CPC study confirmed that CP/CPPS is an important multifactorial problem that affects men of all ages and demographic subgroups. It results in a serious and significant detrimental impact on QoL, and despite the many treatments undergone by patients with CP/CPPS, it appeared that many benefited minimally from empiric therapy [8] .
In a separate analysis, the CPCRN investigated the importance of leukocyte and bacterial counts in the patients enrolled in the CPC study. Significant leukocytosis was noted in the expressed prostatic secretion (EPS) samples in 31% (10+ leukocytes/high-powered field) to 49% (5+ leukocytes/high-powered field). Eight percent of the men had at least one localizing uropathogen based on prostate-specific or semen cultures. One of the most interesting findings in this study was that leukocytes and bacterial counts did not correlate with severity of symptoms. These findings suggested that factors other than leukocytes and bacteria could also contribute to symptoms associated with CP/CPPS [9] .
Men enrolled in the CPC study were followed for 2 years to determine the natural treated history of this condition [10] . The findings suggested that CP/CPPS was, indeed, a chronic condition; however, a group of men who participated in the study had a tendency to improve during the 2 years of follow-up. More than 30% of these subjects (who averaged more than 7 years since diagnosis) reported on the global response assessment that they were moderately or markedly improved at 2 years. Individual patients had experienced dramatic waxing and waning of symptoms. No baseline demographic or clinical factors predicted which men were more or less likely to improve during the 2 years of follow-up.
In an attempt to identify characteristics that might be associated with CP/CPPS, 463 men enrolled in the CPC study were compared with 121 asymptomatic agematched controls [11] . Compared with controls, men with CP/CPPS reported a significantly greater lifetime prevalence of nonspecific urethritis, cardiovascular disease, neurologic disease, psychiatric conditions, and
